10-Q: Nexalin Tech Faces Nasdaq Scrutiny Amidst Financial Woes

Nexalin Technology, Inc. reported a significant increase in revenue but also substantial operating losses and a working capital deficit, while navigating critical Nasdaq listing requirements.

Summary

• Nexalin Technology, Inc. reported a substantial increase in revenue for the third quarter of 2026 compared to the prior year, driven by international sales of component boards.
• However, the company continues to experience significant operating losses and a working capital deficit, raising substantial doubt about its ability to continue as a going concern.
• Nexalin regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split but must still meet the minimum stockholders equity requirement by January 4, 2027.
• The company completed a registered direct offering and entered into an Any Market Purchase Agreement (AMPA) to raise capital, and also issued an unsecured promissory note.
• Acquisition of PONM, Inc. was completed to bolster the Nexalin NeuroCare digital health platform, with ongoing development and integration efforts.
• A pivotal clinical trial for the HALO device for insomnia treatment is underway, with a transition of clinical research organization responsibilities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the company's continued operating losses, substantial doubt about its going concern status, and ongoing challenges with Nasdaq listing requirements, despite some recent financing and regulatory progress.

Positives

• Revenue increased by 331% to approximately $78,301 for the three months ended September 30, 2026, compared to $18,149 in the same period of 2025, primarily due to international sales of component boards.
• Gross margin improved to 74% for the nine months ended September 30, 2026, from 69% in the prior year period.
• The company regained compliance with Nasdaq's minimum bid price requirement on September 30, 2026.
• A Latin America distribution agreement was entered into for the SYNC device, subject to regulatory approvals.
• The acquisition of PONM, Inc. expanded the technology portfolio and supports the Nexalin NeuroCare digital health platform.

Negatives

• The company incurred a net loss of $2,662,068 for the three months ended September 30, 2026, compared to $2,276,311 in the same period of 2025.
• A working capital deficit of approximately $869,153 existed as of September 30, 2026, a significant decrease from a working capital of $3,411,937 at December 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern due to ongoing operating losses and negative cash flows.
• The company must demonstrate compliance with Nasdaq's minimum stockholders equity requirement of $2.5 million by January 4, 2027, with only $263,342 in total stockholders equity as of September 30, 2026.
• Operating expenses increased by 13% to $2,664,978 for the three months ended September 30, 2026, driven by higher professional fees and salaries.
• The company has material weaknesses in internal control over financial reporting related to segregation of duties and IT access controls.

Risks

• The company's continued listing on Nasdaq is subject to demonstrating compliance with the minimum stockholders equity requirement by January 4, 2027, and failure to do so could result in delisting.
• If delisted from Nasdaq, the company could face limited market quotations, reduced liquidity, potential penny stock status, limited news coverage, and difficulty obtaining future financing.
• The company has generated limited operating revenue, experienced recurring operating losses and negative operating cash flows, and faces substantial doubt about its ability to continue as a going concern.
• If sufficient capital cannot be raised through financing arrangements, the company may be required to delay, reduce, or eliminate planned clinical, regulatory, product-development, or commercialization activities.
• The acquisition of PONM, Inc. may not yield anticipated benefits, and the acquired technology may require significant additional development and integration.
• The company depends on GreenLight Ventures, LLC for the continued development, maintenance, and support of the acquired technology, posing a risk related to this related-party arrangement.
• Sales of common stock under financing arrangements, exercise of warrants, and resales by selling stockholders may result in substantial dilution and adversely affect the market price of the common stock.
• Outstanding debt obligations, including the unsecured promissory note, could adversely affect liquidity, limit financial flexibility, and impair the ability to fund operations.

Future Outlook

The company expects to continue incurring operating losses and negative cash flows as it advances its clinical development, regulatory, and product-development initiatives. Additional capital will be required to fund planned operations and strategic initiatives. Management plans include utilizing proceeds from recent financings, pursuing additional equity financing, expanding international revenue, advancing clinical and regulatory programs, and managing operating expenditures. However, the company concluded it does not have sufficient liquidity to fund anticipated operating requirements for at least twelve months.

Management Comments

• Management believes that integrating its proprietary DIFS neuromodulation technology, HALO Clarity device platform, and Nexalin NeuroCare digital health platform may strengthen the Company's clinical development programs, regulatory strategy, and future commercialization efforts.
• Management expects research and development expenses to fluctuate based on the timing and scope of clinical trials and continued investment in the digital health software platform.
• Management expects to continue to incur significant operating losses and negative operating cash flows as it advances its product development, clinical, regulatory, and commercialization initiatives.
• Management intends to seek additional financing, access the ATM Program and the AMPA to the extent available, manage the timing and level of operating expenditures, and pursue revenue opportunities.

Industry Context

StockSavvy.ai notes that Nexalin operates in the highly competitive and rapidly evolving neurostimulation industry, where success depends on clinical trial outcomes, regulatory approvals, intellectual property protection, and market acceptance of its products.

Comparison to Industry Standards

• The company's revenue of $78,301 for the three months ended September 30, 2026, is significantly lower than established medical device companies, indicating an early-stage or niche market focus.
• The substantial operating losses and negative cash flow are common for early-stage medical device companies investing heavily in R&D and clinical trials, but the duration and magnitude raise concerns.
• The company's reliance on equity and debt financings for operations is typical in the biotech/medtech sector, but the ongoing need for capital and the challenges in meeting Nasdaq listing requirements highlight financial vulnerability compared to more mature companies.
• The pursuit of FDA De Novo submission for the HALO device and Q-submission for the SYNC system for Alzheimer's disease are standard regulatory pathways, but the success and timeline are highly uncertain and vary greatly across the industry.

Legal Proceedings

• As of September 30, 2026, the company was not a party to any material legal proceedings.

Related Party Transactions

• Consulting agreement with U.S. Asian Consulting Group, LLC, whose members are shareholders, including a former controller. The agreement was extended and amended, involving monthly fees, stock grants, and semi-annual share awards.
• Lease costs incurred under related-party sublease arrangements with an entity owned by the CEO were $0 for the three months and $18,000 for the nine months ended September 30, 2026.
• Collaboration Agreement with GreenLight Ventures, LLC (GLV) in connection with the acquisition of PONM, Inc. Dr. David Owens, a board member and CMO, holds a minority ownership interest in GLV.
• Wider Come Limited (Wider) is a related party (stockholder) and has been involved in China-related activities and received revenue from sales of devices and products.

Stakeholder Impact

• Shareholders may experience dilution from ongoing equity financings and the issuance of shares for acquisitions and compensation.
• The company's ability to continue as a going concern and meet Nasdaq listing requirements could impact shareholder value and confidence.
• Employees may be affected by the company's financial situation, including potential impacts on bonuses and stock options, as well as the need for continued cooperation in remediation efforts.
• Creditors and noteholders face risks related to the company's liquidity and ability to meet debt obligations, particularly the unsecured promissory note.

Next Steps

• Demonstrate compliance with Nasdaq's minimum stockholders equity requirement of $2.5 million by January 4, 2027.
• Continue advancing clinical development of SYNC and HALO product candidates.
• Pursue applicable regulatory authorizations, including FDA marketing authorization for HALO and CE marking for SYNC.
• Expand the capabilities of the Nexalin NeuroCare platform.
• Protect and enhance the company's intellectual property portfolio.
• Position the company for future commercialization opportunities.
• Continue to manage operating expenditures and pursue revenue opportunities.
• Seek additional financing, including through the ATM Program and AMPA, as available.

Key Dates

Recommendation

While the company shows revenue growth and has regained Nasdaq bid price compliance, the significant operating losses, going concern doubts, and ongoing need for capital, coupled with material weaknesses in internal controls, present substantial risks. The potential for future dilution and Nasdaq delisting remains a concern. The positive developments in clinical trials and strategic acquisitions are noted, but the financial precariousness warrants a cautious 'hold' stance until greater financial stability and regulatory clarity are achieved.

Keywords

neurostimulation, medical device, clinical trial, FDA, Nasdaq, capital raise, going concern, stockholders equity